Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

RESPINE

Financiado

REgenerative therapy of intervertebral disc a double blind phase 2b trial of in...

REgenerative therapy of intervertebral disc a double blind phase 2b trial of intradiscal injection of mesenchymal stromal cells in degenerative disc disease of the lomber SPINE unresponsive to conventional therapy The World Health Organisation (WHO) has included low back pain in its list of twelve priority diseases. Notably, Degenerative disc disease (DDD) presents a large, unmet medical need which results in a disabling loss of mechanical... ver más

30/06/2023

CENTRE HOSPITALIER...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 19 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-06-30

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

SC1-PM-11-2016-2017: Clinical research on regenerative medicine

I+D

Cerrada hace 8 años

0% 100%

19 Participantes

CENTRE HOSPITALIER UNIVERSIT...

933.54K€ | Lider

UPNA

351.75K€ | Participante

UNIVERSITE TOULOUSE III - Pa...

N.D. | Participante

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 78 meses Fecha Inicio: 2016-12-09
Fecha Fin: 2023-06-30

Líder del proyecto

CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER

TRL 4-5

Presupuesto del proyecto 6M€

Descripción del proyecto The World Health Organisation (WHO) has included low back pain in its list of twelve priority diseases. Notably, Degenerative disc disease (DDD) presents a large, unmet medical need which results in a disabling loss of mechanical function. Today, no efficient therapy is available. Chronic cases often receive surgery, which may lead to biomechanical problems and accelerated degeneration of adjacent segments. Our consortium partners have developed and studied stem cell-based, regenerative therapies with encouraging results in phase 1 and 2a trials. Patients exhibited rapid and progressive improvement of functional and pain indexes by 50% within 6 months and by 65% to 78% after 1 year with no side effects. In addition, MRI T2 relaxation measurements demonstrated a significant improvement. To develop the world’s first rigorously proven, effective treatment of DDD, RESPINE aims to assess, via a multicentre, randomized, controlled, phase 2b clinical trial including 112 patients with DDD, the efficacy of an allogenic intervertebral mesenchymal stem cell (MSC)-based therapy. This innovative therapy aims to rapidly (within 3 months) and sustainably (at least 24 months) reduce pain and disability. In addition, the consortium aims to provide new knowledge on immune response & safety associated with allogeneic BM-MSC intradiscal injection. This simple procedure would be cost-effective, minimally invasive, and standardised. The transfer to the clinic will be prepared at a cost below 10k€ thanks to the strategy of production of allogenic cells, automation & EU standardisation. At the end of the RESPINE trial, we aim to propose a broadly available and clinically applicable treatment for DDD, marketed by European SMEs.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores